Redeye comments on SSH’s Q4 report, which was softer than expected following the January guidance re...
Redeye is optimistic after Medivir's Q4 report. The new programme in osteogenesis imperfecta holds s...
Redeye provides a research update following the Q4 report recently published by Isofol.
Redeye retains its positive view of Avensia despite lowering our Base Case and forecasts.
Upsales redovisade ökad nettoomsättning och EBIT i det fjärde kvartalet.
Redeye returns with an update following Elicera’s Q4 earnings release.
Redeye reviews SynAct Pharma's Q4 report. A new European study in respiratory insufficiency was init...
Redeye provides a research update following the Q4 report published by Cinclus earlier today.
Redeye comments on Avensia’s Q4 report, showing softer margins than expected.
Following Insplorion’s recent announcement to divest its core hydrogen business, reported Q4 figures...
Redeye provides an initial take following Senzime’s Q4 2025 report.
Click below to watch the full video with CEO Philip Siberg's presentation of the company's report.
Given that Thunderful’s shares will soon be delisted, the quarterly result is not important for shar...
Actic's positive trends, with strong cash flows and lower leverage, continued in Q4.
Redeye updates on Hacksaw after Q4-results which saw somewhat stronger-than-expected profitability w...
Redeye updates its estimates and valuation after Relais’ Q4 2025 report.
* Solid earnings momentum in Paving services * Divestment brings net cash position and dividend * M&...
Smart Eye delivered a strong Q4 within Automotive, significantly outperforming our expectations, whi...
Redeye comments on Camurus' Q4 report 2025, which was below our estimates due to a large sequential ...
Redeye provides an update following Corline’s Q4 2025 report.
